Clinical advancement in the management of mutant isocitrate dehydrogenase (IDH) cancers
{{output}}
The use of mutant isocitrate dehydrogenase (mIDH) inhibitors has been investigated and has shown significant improvement in survival outcomes in patients with a range of mIDH cancers, including acute myeloid leukaemia (AML), cholangiocarcinoma (CCA), glioma an... ...
